BSE · 524768
Emmessar Biotech & Nutrition Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹3 Cr with net profit ₹1 Cr — a 29.43% net margin, versus 18.19% the period before.
Shareholding
As of 2026-06-30
- Promoter59.53%
- Public40.28%
- DII0.2%
7,136 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.32× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Chemicals · ranked #128 of 159 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Pidilite Industries Ltd. | ₹1,65,887 Cr | 286.45 | 15.31 | 22.61% | 16.77% |
| Solar Industries India Ltd. | ₹1,63,606 Cr | 298.74 | 26.07 | 26.72% | 17.05% |
| SRF Ltd. | ₹78,369 Cr | 134.68 | 5.58 | 13.07% | 11.9% |
| Linde India Limited | ₹57,332 Cr | 740.36 | 13.44 | 12.48% | 0.18% |
| Gujarat Fluorochemicals Ltd. | ₹50,334 Cr | 461.91 | 6.45 | 7.3% | 11.49% |
| Godrej Industries Ltd. | ₹43,559 Cr | 98.05 | 3.9 | 11.1% | 5.58% |
| Navin Fluorine International Ltd. | ₹38,957 Cr | 183.04 | 9.79 | 16.69% | 20.02% |
| Himadri Speciality Chem Limited | ₹38,845 Cr | 193.44 | 8.25 | 15.96% | 16.12% |
| Deepak Nitrite Ltd. | ₹22,840 Cr | 103.95 | 3.91 | 9.43% | 6.98% |
| Deepak Fertilisers & Petrochemicals Corp Ltd. | ₹20,530 Cr | 147.31 | 3 | 10.77% | 6.41% |
| Emmessar Biotech & Nutrition Ltd.(this company) | ₹13 Cr | 29.06 | 1.56 | 5.37% | 119.44% |
AI analysis
AI-generated · google/gemini-2.5-flashEmmessar Biotech & Nutrition Ltd. (524768) operates with a market capitalization of Rs 12 Cr. The company reported annual revenue of Rs 2.5473 Cr in March 2024. Its latest reported EPS is 0.87. The promoter holding stands at 59.5285%, with no pledged shares.
Positives
- +The company has a very low debt-to-equity ratio of 0.01.
- +The profit margin is high at 119.44%.
Negatives
- −Annual revenue decreased by 8.03% from Rs 2.7699 Cr in Mar 2023 to Rs 2.5473 Cr in Mar 2024.
- −Quarterly revenue consistently declined from Rs 0.1 Cr in Dec 2024 to Rs 0.09 Cr in Mar 2026.
- −Quarterly net profit was negative, at -Rs 0.07 Cr, in Mar 2025.
Financial performance
Annual revenue for Emmessar Biotech & Nutrition Ltd. declined to Rs 2.5473 Cr in Mar 2024 from Rs 2.7699 Cr in Mar 2023. Net profit increased to Rs 0.7496 Cr in Mar 2024 from Rs 0.5038 Cr in Mar 2023. Quarterly revenue has shown a declining trend, from Rs 0.1 Cr in Dec 2024 to Rs 0.09 Cr in Mar 2026.
Profitability & returns
The company reported a profit margin of 119.44%. Return on equity (ROE) was 5.37%, and return on capital employed (ROCE) was 6.6919%. Earnings per share (EPS) for the latest available period was 0.87, with an annual EPS of 1.48 in Mar 2024.
Balance sheet
The company maintains a low debt-to-equity ratio of 0.01, indicating minimal reliance on debt financing. The book value per share is Rs 16.24.
Ownership & pledges
Promoter holding is 59.5285% as of June 30, 2026, with no shares pledged. The total number of shareholders was 7136 as of June 30, 2026.
Regulatory & surveillance
There is no information provided regarding any surveillance measures or specific regulatory actions for Emmessar Biotech & Nutrition Ltd.
Data as of — price: 2026-07-29 · financials: Mar 24 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Emmessar Biotech & Nutrition Ltd.share price & fundamentals
